All Stories

  1. Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population
  2. Fibrillary glomerulonephritis: An apparent familial form?
  3. Home hemodialysis needs you!
  4. Home hemodialysis: Infrastructure, water, and machines in the home
  5. Personal viewpoint: Limiting maximum ultrafiltration rate as a potential new measure of dialysis adequacy
  6. Green Dialysis: The Environmental Challenges Ahead
  7. Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home
  8. The carbon footprint of an Australian satellite haemodialysis unit
  9. Dialysis in Australia and New Zealand
  10. Risk Factors for Dialysis Withdrawal: An Analysis of the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, 1999–2008
  11. Solar-Assisted Hemodialysis
  12. Personal viewpoint: Hemodialysis-Water, power, and waste disposal: Rethinking our environmental responsibilities
  13. Home Hemodialysis in Australia and New Zealand: How and Why it has been Successful
  14. Alternate Night Nocturnal Hemodialysis: The Australian Experience
  15. Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations
  16. How Australian nephrologists view home dialysis: Results of a national survey
  17. Green nephrology in Australia: recirculating reject water
  18. Review: Understanding sorbent dialysis systems
  19. Conserving water in and applying solar power to haemodialysis: ‘Green Dialysis’ through wiser resource utilization
  20. International Variations and Trends in Home Hemodialysis
  21. Using water wisely: New, affordable, and essential water conservation practices for facility and home hemodialysis
  22. Home hemodialysis in Australia and New Zealand: Practical problems and solutions
  23. Reusing Dialysis Wastewater: The Elephant in the Room
  24. Who will replace me? A renal physician’s lament
  25. Changes in hemoglobin and albumin concentration during nocturnal home hemodialysis
  26. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis
  27. Chronic maintenance hemodialysis: Making sense of the terminology
  28. Comparison of biochemical, haematological and volume parameters in two treatment schedules of nocturnal home haemodialysis
  29. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis
  30. Nocturnal haemodialysis: An Australian cost comparison with conventional satellite haemodialysis (Review Article)
  31. Dose of haemodialysis
  32. Duration and frequency of haemodialysis therapy
  33. Haemodialysis anticoagulation and adequacy
  34. Dialysis membranes
  35. Blood urea sampling methods
  36. Water quality for haemodialysis
  37. 'Flexible' or 'lifestyle' dialysis: Is this the way forward?
  38. Intradialytic serum protein concentrations differ between nightly nocturnal and conventional haemodialysis
  39. Nocturnal haemodialysis in Australia and New Zealand (Review Article)
  40. Nocturnal dialysis: Comparing six night/week with alternate night therapy
  41. Beta-2-Microglobulin in nocturnal hemodialysis - A comparative study in low and high flux dialysers
  42. Nocturnal Hemodialysis in Australia
  43. Recommendations for the use of icodextrin in peritoneal dialysis patients. Review Article
  44. Nocturnal Dialysis - The 1st Australian Experience
  45. Nocturnal Haemodialysis - A Preliminary Cost Comparison with Conventional Haemodialysis in Australia
  46. A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport's syndrome
  47. MICROSURGICAL “DE‐CONSTRUCTION” OF THE AV FISTULA (AVF) IN RENAL TRANSPLANT (TX) RECIPIENTS
  48. MICROSURGICAL "DE-CONSTRUCTION" OF THE AV FISTULA (AVF) IN RENAL TRANSPLANT (TX) RECIPIENTS
  49. Arteriovenous access fistulae diminish cardiac reserve, anaerobic threshold and work capacity: A case for fistula closure in stable renal transplant recipients
  50. An education programme promoting organ donation for 13?14 year old schoolchildren
  51. Enalapril overdose treated with angiotensin infusion
  52. Inducing diagnostic rules for glomerular disease with the DLG machine learning algorithm
  53. Cyclosporin A and mefenamic acid in a renal transplant patient
  54. Diclofenac-Associated Interstitial Mucinosis
  55. Caught in the Act!
  56. CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD): AN ESTABLISHED TREATMENT FOR ENDSTAGE RENAL FAILURE
  57. Renal Vein Renin Activity and Prostaglandins A and E in Hypertension
  58. Acute Cardiopulmonary Decompensation and Complement Activation During Hemodialysis